New drugs for type 2 diabetes mellitus: what is their place in therapy?
about
Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive careThe Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonFurther improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular diseaseThe use of animal models in diabetes research.Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids.Antidiabetic actions of an estrogen receptor β selective agonist.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Randomized controlled trial to evaluate the effects of combined progressive exercise on metabolic syndrome in breast cancer survivors: rationale, design, and methodsEvaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes.Pharmacological management of metabolic syndrome and its lipid complications.Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in JapanOcimum basilicum extract exhibits antidiabetic effects via inhibition of hepatic glucose mobilization and carbohydrate metabolizing enzymesBarriers to glycemic control in youth with type 1 diabetes and type 2 diabetes.Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.Oral salmon calcitonin--pharmacology in osteoporosis.Patient adherence to medication requirements for therapy of type 2 diabetes.Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.A review of gliptins in 2011.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic ratA Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme.Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study.Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.Full length amylin oligomer aggregation: insights from molecular dynamics simulations and implications for design of aggregation inhibitors.Insulin resistance: a risk marker for disease and disability in the older person.Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy.Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.Metabolic Syndrome and Neuroprotection.
P2860
Q28082385-B81BD624-90A4-48C1-8913-AC3ACC1E5973Q33630394-E48BE232-F473-47A8-9402-FACA86DB5834Q33785197-2B41866A-48D5-477C-A025-3AD5800C87B3Q33932718-6B095B3A-4150-4B58-8EE5-80F22091F6ECQ33939256-00D464BC-CA3D-435E-A0F6-5EFD256FE413Q34255921-3422A00A-3B9B-490A-AC92-A4AA3B92C9F5Q34288470-7EB2545F-A589-45B5-884B-F32C6AFEA1D7Q34324370-6F00CA21-5A50-4393-82CD-E36367C42FC2Q34620693-55C060C8-70BE-4835-9B7B-EA09D58D7B57Q35141411-10646332-50E4-4ACC-8DF6-E20DC8E99F53Q35153053-7DC49EBF-F0D0-4AD1-804F-BCFF1C6731ACQ35832189-44E792F7-DA44-46C9-9704-FB968DA7972AQ36093802-BF2B56C7-D164-4D8F-B0F8-0BA371542B4CQ36402230-20287AF3-DB04-4D12-8804-143C6B39511EQ37064419-5F2A5059-6900-4AFC-9C94-05FA867C9194Q37621150-A61B3FF0-1D18-4D99-9958-3A2EDD3D50FFQ37766286-3BAB8C1A-340C-4863-BE5C-F5B329714964Q37772523-2D686B0A-960E-4736-8CD9-D03FAB2D3128Q37798836-F4A35283-EF47-4C31-8A4B-79ED1A86B26CQ37840269-3337BFC7-10C4-4B2E-A4C6-967A3836849BQ37841554-7EAD21A4-BE81-4A23-B9C8-0EFD5C5F1C19Q37965612-5C18CE88-5E04-478D-8A1A-2F913CF6EBB1Q38071706-4E96267A-CF67-43BB-986D-61C78603C6A9Q38152405-EF60649D-CD4D-453D-847C-26DD72D6A5D1Q38202207-EE07319D-3411-4214-86F7-10C2EBD09D28Q38628118-769B1471-FFEA-4825-9065-00C104F0C1C6Q38885892-24B76DB4-3E7E-43F2-A625-7B8A4652D37DQ42326757-583D4AAD-B15C-4E78-811F-423497CAD4EBQ43202587-33AE3C3C-A991-4088-A0B8-8E14FA8824DFQ43826389-E2BD267D-416D-4EC2-BB9C-CF3FA4DC0B56Q45016854-24FCFB8E-76E9-44CD-8264-68ECC522E27EQ45330314-12D8741E-BD33-4B8F-96FB-F3B17A9B70C3Q46595958-37EEFD42-15A9-4F43-81E7-F31325510297Q47374720-5B38EC6D-C464-483C-BAE8-A1015EBF857DQ51279076-6A50B732-8D52-4E8F-A3FE-D9D4B5E4D0A8Q51323275-25FB194A-9208-40C3-8652-9E399F02D3F6Q51354362-A72F6A4B-82DB-4121-9BCD-3D84D95E646EQ51357963-CBA5A436-6174-4301-BFEA-7775736920E9Q53687232-D961B868-6194-4F14-9A8F-E5BF847F4422
P2860
New drugs for type 2 diabetes mellitus: what is their place in therapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@en
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@nl
type
label
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@en
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@nl
prefLabel
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@en
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@nl
P1433
P1476
New drugs for type 2 diabetes mellitus: what is their place in therapy?
@en
P2093
Andrew J Krentz
Mayank B Patel
P304
P356
10.2165/00003495-200868150-00005
P577
2008-01-01T00:00:00Z
P6179
1027038745